您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
莊再成
莊再成
所属职位: 首席运营官
所属公司:

武汉博沃生物科技有限公司

Dr. Chong obtained his BSc (1978) and PhD (1983) from the department of Biochemistry in the University of Alberta, Edmonton, Canada. He was trained as a protein chemist and specialized in peptide synthesis for protein structure and function studies. After 2 years as a MRC postdoctoral in the University of British Columbia, Dr. Chong moved to Toronto and had spent 15 years at Connaught Laboratory Limited (now called Sanofi Pasteur) in human vaccine research and development. During his tenure there as a Research Scientist (July/1985) and Director (July/1994), Dr. Chong had developed two human vaccines, ProHibit against H. influenzae type b (Hib) and the component pertussis vaccine, and also took a synthetic peptide-based HIV vaccine to Phase I clinical trials in 1994.  Dr. Chong moved to New York in 2000 and joined United Biomedical Inc. (UBI) where he helped developing a peptide-based animal Foot-Mouth Disease vaccine for pig that is currently licensed in China. Dr. Chong was recruited and joined NHRI in 2003 and as the founder established the Vaccine Research and Development Center (VRDC). To facilitate and implement the Taiwanese Government Vaccine R&D, Self-Manufacturing and Supply strategic plans, Dr. Chong had developed and took both cell-based H5N1 flu vaccine and EV71 vaccine to phase I clinical trials. In March 2018, Dr. Chong joined BravoVax, Wuhan. Dr. Chong has authored over 200 original research articles and has over 80 patents filed and/or granted.

微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务